Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/WQZ_7860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Implementing guideline-recommended anticoagulation therapy is vital to prevent stroke in individuals with atrial fibrillation (AF). Through a MasterClass series of seven episodes, two expert cardiologists examine risk factors, screening strategies, and data from clinical trials, as well as real-world evidence, to offer best practices to detect and treat AF. Upon completion of this activity, participants should be better able to: Describe the impact and burden of undiagnosed AF on the prevalence of stroke and other cardiovascular events, and ultimately on the healthcare system and society; Implement interprofessional screening strategies to increase rates of AF diagnosis in at-risk patients, in accordance with guidelines and leveraging advances in technology; and Develop personalized, evidence-based anticoagulant treatment plans for patients diagnosed with AF using clinical tri

Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT therapy based on disease risk factors; use of JAK inhibitor in non-HCT settings; practical dosing and safety management considerations; and the emergence of novel targeted and combinatorial strategies in the MF setting. Watch this informative update on personalized care for patients with MF! Upon completion of this activity, participants should be better able to: Discuss patient- and disease-related features of MF that i

Go online to PeerView.com/FTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed. There is also an increasing need for new ways to measure response to immunotherapies as they transition to early-stage, curative-intent settings in different solid tumors. Pathologic response assessment has emerged as a promising approach for evaluating the impact of neoadjuvant immunotherapy in lung, breast, and other cancers. However, limited guidance has been available on how to define and measure pathologic response,

Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial c

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cel

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL

Go online to PeerView.com/DFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody platforms—including agents directed against targets such as CD38 and BCMA—have proven efficacy in a range of multiple myeloma (MM) treatment settings and have clear treatment roles across the spectrum of care, from newly diagnosed MM to relapsed/refractory disease. Additionally, a new wave of immune-based treatments in the form of bispecific T-cell–engaging antibodies shows a great deal of promise and may soon add another layer of complexity to the selection and use of antibody platforms in MM. This activity features a panel of hematology-oncology experts illustrating the clinical implications of current and emerging evidence that supports an expanded role for therapeutic use/planning of antibody and immunotherapy options in MM. Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations surroun

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, selection of appropriate postremission maintenance, and the use of novel conditioning to expand access to HCT for AML populations with unmet medical needs. Upon completion of this activity, participants should be better able to: Characterize baseline disease- and patient-related features that can inform prognosis and facilitate treatment decisions for transplant-eligible patients with AML; Integrate novel therapies into ind

Go online to PeerView.com/FSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. After many years of slow progress, the treatment arsenal has finally expanded and more hope is on the horizon for patients with small cell lung cancer (SCLC). Notable advances such as chemo-immunotherapy in the first-line setting and lurbinectedin in the second-line setting have now become guideline-recommended standards of care and propelled the treatment of SCLC forward. Further research efforts are focused on understanding the underlying biology and potential subtypes of SCLC, what biomarkers may be useful in refining treatment selection, and evaluation of novel therapeutic options and rational combinations. In this PeerView Live Candid Conversations & Clinical Consults symposium, based on a recent live symposium, leading experts weave together the latest evidence on standard-of-care therapies and the evolving data on new/emerging approaches to provide a big-picture overv

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their results be interpreted to inform clinical decisions? How can biomarker testing information guide optimal treatment selection and sequencing throughout the NSCLC disease continuum, including in earlier disease settings in which adjuvant targeted therapy is now available? These and other key questions are answered in this new educational activity. Experts help you prepare to meet the rising challenges and opportunities that

Go online to PeerView.com/YCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An evolving understanding of the role of B cells in pathophysiology of multiple sclerosis (MS) and the demonstrated success of other B cell–targeted therapies have led to great interest in the promise of Bruton tyrosine kinase (BTK) inhibitors as a novel MS treatment class. Compared with anti-CD20 monoclonal antibodies, BTK inhibitors are understood to offer the promise of greater selectivity that leaves healthy B cells intact, as well as the ability to cross the blood–brain barrier and affect both the peripheral and central nervous systems. Four BTK inhibitors are now in phase 3 trials, with others in earlier stages of investigation. In this activity, based on a recent live symposium, expert speakers review the pathophysiologic rationale for BTK inhibition and discuss the emerging trial data on these agents. Upon completion of this activity, participants should be better able t

Go online to PeerView.com/PJD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New, modern antibody–drug conjugates (ADCs) have emerged as promising additions to the treatment arsenal for patients with lung cancer, with the first HER2-targeting ADC recently gaining FDA approval for patients with unresectable or metastatic NSCLC whose tumors have HER2 mutations. Clinical trials are also underway with novel ADCs targeting HER3, TROP2, CEACAM5, and MET, among others, and have been yielding encouraging results to date. What are the unique structural and mechanistic features as well as efficacy and safety profiles of these ADCs? Where are they likely to best fit in the NSCLC treatment algorithms? What practical considerations should be taken into account when integrating these therapies into treatment plans? These and other topics are explored in this unique educational activity, based on a recent live symposium, in which experts compete to answer a series of c

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding patient access to CAR-T therapy. Expert panelists discuss the key data supporting CAR-T therapy in hematologic cancers and provide guidance on principles of outpatient cellular therapy, lessons derived from the outpatient experience with stem cell transplantation, and strategies to overcome barriers to patient selection, adverse events, and adequate staffing. Upon completion of this activity, participants should be better

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers. Upon completion of this activity, participants should be better

Go online to PeerView.com/FFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the number of approved treatment strategies in renal cell carcinoma (RCC) grows, there are new opportunities to provide personalized medicine to patients in a variety of settings. Multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) are now options in the frontline treatment of advanced disease, while recent data also show that immunotherapy-based combinations may improve survival in patient subpopulations with poor prognostic features. In this activity, based on a recent live symposium, a panel of experts reviews the latest efficacy and safety evidence for approved and emerging strategies for the treatment of patients with advanced RCC in the frontline and refractory settings and engages in discussions of relevant patient cases that will provide insight on bringing these ther

Go online to PeerView.com/PNF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. “Treatment intensification”—or the use of combination treatment strategies—has now become the standard of care for patients with metastatic hormone-sensitive prostate cancer. Shown to extend overall survival beyond single-agent treatment, these combinations of androgen deprivation therapy and other effective treatments such as docetaxel chemotherapy and/or novel androgen axis inhibitors have resulted in regulatory approvals and updates to clinical practice guidelines. Given the range of effective options and more on the horizon, as additional agents and combinations are also being studied in localized and advanced disease, how do clinicians ensure that the right patients are getting the right treatments? In this activity, based on a recent live symposium, expert faculty pair in-depth updates on efficacy and safety data on approved and emerging regimens with case-based discussion

Go online to PeerView.com/CUN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to apply the “new rules” of management to veno-occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) for your patients at risk for this hematopoietic stem cell transplantation (HCT) complication? Find out in this PeerView Clinical Consult video recorded at the 2023 Tandem Meetings. Watch as our panelists give the latest guidance on VOD/SOS management, while discussing adult and pediatric case scenarios designed to inform on risk assessment, diagnostic confirmation, severity grading, and treatment. Throughout, the experts will highlight how modern care principles can confirm a diagnosis, determine the presence of organ dysfunction, and prompt the initiation of timely supportive care and pharmacologic treatment. Don’t miss this opportunity to get the latest, most effective approaches to VOD/SOS management and received CME credit! Upon completion of this ac

Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize e

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuance

Go online to PeerView.com/KYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The visual guide to hypertrophic cardiomyopathy (HCM) you’ve been waiting for is here! In contemporary care, patients with HCM have options that may reduce the need for invasive treatments. This engaging presentation is perfect for both visual and auditory learners to update their understanding of HCM, tune in to the signs and symptoms that should raise suspicion, and learn best practices to confirm a diagnosis of HCM. Once diagnosed, you’ll need to know the latest data on cardiac myosin inhibitors and practical guidance for integrating them into patient care. This activity delivers on all of the above—set aside some time and click “play” today! Upon completion of this activity, participants should be better able to: Recognize clinical characteristics and/or features that suggest the presence of HCM; Accurately diagnose patients with suspected HCM using expert guidance and the l